Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by MV Capital Management Inc.

MV Capital Management Inc. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.1% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 199 shares of the medical research company’s stock after buying an additional 23 shares during the period. MV Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $116,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TMO. Gotham Asset Management LLC lifted its stake in shares of Thermo Fisher Scientific by 47.5% during the third quarter. Gotham Asset Management LLC now owns 2,654 shares of the medical research company’s stock worth $1,343,000 after purchasing an additional 855 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its holdings in Thermo Fisher Scientific by 54.3% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 12,107 shares of the medical research company’s stock worth $6,128,000 after acquiring an additional 4,260 shares during the period. Adage Capital Partners GP L.L.C. grew its position in Thermo Fisher Scientific by 5.9% in the third quarter. Adage Capital Partners GP L.L.C. now owns 334,124 shares of the medical research company’s stock valued at $169,124,000 after acquiring an additional 18,739 shares in the last quarter. Evergreen Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 4.1% during the third quarter. Evergreen Capital Management LLC now owns 2,725 shares of the medical research company’s stock valued at $1,380,000 after purchasing an additional 108 shares during the period. Finally, Elevatus Welath Management boosted its stake in shares of Thermo Fisher Scientific by 4.8% in the third quarter. Elevatus Welath Management now owns 1,168 shares of the medical research company’s stock valued at $591,000 after purchasing an additional 53 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $533.93 on Wednesday. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The firm’s 50 day moving average is $574.71 and its two-hundred day moving average is $563.50. The firm has a market capitalization of $203.81 billion, a P/E ratio of 34.25, a PEG ratio of 2.58 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be given a dividend of $0.39 per share. The ex-dividend date is Friday, June 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Insider Activity

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,238,340.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The disclosure for this sale can be found here. Insiders sold 22,000 shares of company stock worth $12,532,780 over the last three months. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on TMO shares. Robert W. Baird cut their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. Jefferies Financial Group reiterated a “buy” rating and issued a $650.00 price target (up previously from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. The Goldman Sachs Group lifted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. HSBC increased their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Finally, Citigroup assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $606.47.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.